Abstract | BACKGROUND: METHODS: Both study groups received subcutaneously aqueous solutions of AT2 antagonist ( PD123319 - 1 mg/kg/day) and AT1 antagonist (L158809 - 1 mg/kg/day), respectively, 6 times per week. On day 90, some rats (5 /group) were sacrificed by excision of the liver under anesthesia, in order to assess the hepatic hydroxyproline (HP), malondialdehyde (MDA), total glutathione, superoxide dismutase (SOD) activity and TGFbeta-1. The remaining rats were maintained to observe the survival rate. RESULTS: All CDD rats developed liver cirrhosis. However, the tissue TGF and HP decreased in AT1 antagonist group in comparison with the other two groups. All groups of CDD rats showed strong adipose hyperoxidation. The AT1 antagonist group demonstrated a markedly improved survival rate in comparison to the other two groups. CONCLUSION: Hepatic fibrosis progression in the AT1 antagonist group was slower than that in the other groups. This observation suggests that AT1 antagonists delayed the progression of liver failure, which thus led to an improved survival rate.
|
Authors | Kaoru Iwata, Tetsuro Sohda, Makoto Irie, Yasuaki Takeyama, Akira Anan, Satoshi Shakado, Shotaro Sakisaka |
Journal | Journal of gastrointestinal and liver diseases : JGLD
(J Gastrointestin Liver Dis)
Vol. 17
Issue 1
Pg. 21-5
(Mar 2008)
ISSN: 1841-8724 [Print] Romania |
PMID | 18392239
(Publication Type: Journal Article)
|
Chemical References |
- Angiotensin II Type 2 Receptor Blockers
- Antihypertensive Agents
- Imidazoles
- Pyridines
- Tetrazoles
- Vasoconstrictor Agents
- Angiotensin II
- PD 123319
- L 158809
- Choline
|
Topics |
- Angiotensin II
(antagonists & inhibitors)
- Angiotensin II Type 2 Receptor Blockers
- Animals
- Antihypertensive Agents
(therapeutic use)
- Choline
- Disease Models, Animal
- Imidazoles
(therapeutic use)
- Lipid Peroxidation
(drug effects)
- Liver Cirrhosis
(etiology, metabolism, prevention & control)
- Male
- Pyridines
(therapeutic use)
- Rats
- Rats, Inbred F344
- Tetrazoles
(therapeutic use)
- Vasoconstrictor Agents
(therapeutic use)
|